| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer
|
Palma dos Reis, Ana Filipa
|
|
|
|
2 |
p. 115-127
|
artikel
|
| 2 |
Biomarkers Towards New Era of Therapeutics for Metastatic Renal Cell Carcinoma
|
Mizuno, Ryuichi
|
|
|
|
2 |
p. 61-69
|
artikel
|
| 3 |
Clinical Trials Corner
|
Parikh, Mamta
|
|
2018
|
|
2 |
p. 175-177
|
artikel
|
| 4 |
Clinical Trials Corner
|
Parikh, Mamta
|
|
2019
|
|
2 |
p. 141-142
|
artikel
|
| 5 |
Clinical Trials Corner: Adding up in Adjuvant
|
Parikh, Mamta
|
|
|
|
2 |
p. 143-144
|
artikel
|
| 6 |
Clinical Trials Corner: A New Look at Cytoreductive Nephrectomy
|
Parikh, Mamta
|
|
|
|
2 |
p. 113-114
|
artikel
|
| 7 |
Clinical Trials Corner: Translating Benefit to the Bone
|
Parikh, Mamta
|
|
|
|
2 |
p. 117-118
|
artikel
|
| 8 |
Diagnostic Imaging for Solid Renal Tumors: A Pictorial Review
|
van Oostenbrugge, Tim J.
|
|
2018
|
|
2 |
p. 79-93
|
artikel
|
| 9 |
Evaluating the Optimal Duration of Immunotherapy in Kidney Cancer
|
Parikh, Mamta
|
|
|
|
2 |
p. 105-107
|
artikel
|
| 10 |
Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249)
|
Synold, Timothy W.
|
|
2019
|
|
2 |
p. 111-118
|
artikel
|
| 11 |
Evolving Frontline Treatment Landscape for Advanced or Metastatic Renal Cell Carcinoma
|
Jain, Rohit K.
|
|
|
|
2 |
p. 71-79
|
artikel
|
| 12 |
Examining the Association of Academic Rank and Productivity with Metrics of Twitter Utilization Amongst Kidney Cancer Specialists
|
Salgia, Nicholas J.
|
|
|
|
2 |
p. 103-109
|
artikel
|
| 13 |
First-Line Immune Checkpoint Inhibitor-Based Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review
|
Thana, Myuran
|
|
|
|
2 |
p. 81-92
|
artikel
|
| 14 |
Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)
|
|
|
|
|
2 |
p. 119
|
artikel
|
| 15 |
Geographical Differences in Kidney Cancer Outcomes of Patients Treated with Immunotherapy: A Systematic Review
|
Gonçalves, Vinicius Knackfuss
|
|
|
|
2 |
p. 129-136
|
artikel
|
| 16 |
Hereditary Renal Cell Carcinoma
|
Dawsey, Scott J.
|
|
|
|
2 |
p. 83-93
|
artikel
|
| 17 |
Imaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future Challenges
|
Fournier, Laure
|
|
2017
|
|
2 |
p. 107-114
|
artikel
|
| 18 |
Immune Gene Signature Expression Differs between African American and Caucasian Patients with Renal Cell Carcinoma
|
Ghatalia, Pooja
|
|
|
|
2 |
p. 109-114
|
artikel
|
| 19 |
Impact of SARS-CoV-2 Pandemic on Kidney Cancer Management
|
Bersanelli, Melissa
|
|
|
|
2 |
p. 93-106
|
artikel
|
| 20 |
Intensity Modulated Radiotherapy is a Well-Tolerated and Effective Treatment for the Long-Term Control of Intra-Abdominal and Retroperitoneal Oligometastatic Renal Cell Cancer
|
Maund, Isabella
|
|
2018
|
|
2 |
p. 103-113
|
artikel
|
| 21 |
miR-22 Regulates Invasion, Gene Expression and Predicts Overall Survival in Patients with Clear Cell Renal Cell Carcinoma
|
Gong, Xue
|
|
2019
|
|
2 |
p. 119-132
|
artikel
|
| 22 |
Nivolumab: 5 Years Since FDA Approval of the First Checkpoint Inhibitor for Renal Cell Carcinoma
|
Tsimafeyeu, Ilya
|
|
|
|
2 |
p. 63-71
|
artikel
|
| 23 |
Non-Clear Cell Renal Cell Carcinoma: Current Management and Best Practice
|
Salgia, Meghan
|
|
2017
|
|
2 |
p. 99-105
|
artikel
|
| 24 |
Nutritional Predictors of Perioperative Complications and Mortality Following Nephrectomy for Renal Malignancies: A Population-Based Analysis
|
Arora, Karan
|
|
2018
|
|
2 |
p. 147-174
|
artikel
|
| 25 |
Optimal First-Line Treatment of Metastatic Renal-Cell Carcinoma: A Network Meta-Analysis
|
Hahn, Andrew W.
|
|
2018
|
|
2 |
p. 115-121
|
artikel
|
| 26 |
Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107
|
Twardowski, Przemyslaw W.
|
|
2017
|
|
2 |
p. 123-132
|
artikel
|
| 27 |
Partial Nephrectomy is the Surgical Treatment of Choice for (Most) Complex Localized Renal Tumors
|
Herlemann, Annika
|
|
2018
|
|
2 |
p. 73-77
|
artikel
|
| 28 |
PBRM1 Mutations as a Predictive Biomarker for Immunotherapy in Metastatic Renal Cell Carcinoma: A Systematic Review
|
Dias Carneiro, André Paternò Castello
|
|
|
|
2 |
p. 79-92
|
artikel
|
| 29 |
Positive Surgical Margins After Partial Nephrectomy: A Systematic Review and Meta-Analysis of Comparative Studies
|
Ficarra, Vincenzo
|
|
2018
|
|
2 |
p. 133-145
|
artikel
|
| 30 |
Real-World Data from a Metastatic Renal Cell Carcinoma Community-Academic Registry: Comparative Outcomes of Progression Free Survival and Overall Survival
|
Ramalingam, Sundhar
|
|
2019
|
|
2 |
p. 133-140
|
artikel
|
| 31 |
Reconciling the Role of Vascular Endothelial Growth Factor-Targeted Therapies in Adjuvant Renal Cell Carcinoma Treatment
|
Kim, Won
|
|
2018
|
|
2 |
p. 95-102
|
artikel
|
| 32 |
Renal Cancer Without Primary Cancer in the Kidney: Extra-Renal TFE3 Translocation Associated Renal Cell Carcinoma
|
Petrinec, Benjamin
|
|
|
|
2 |
p. 107-112
|
artikel
|
| 33 |
Renal Cell Carcinoma with Inferior Vena Cava Extension: Can Classification Be Optimized to Predict Perioperative Outcomes?
|
Leibovich, Bradley C.
|
|
|
|
2 |
p. 111-115
|
artikel
|
| 34 |
Skeletal-Related Events in Patients with Metastatic Renal Cell Carcinoma: A Systematic Review
|
Jang, Albert
|
|
|
|
2 |
p. 93-102
|
artikel
|
| 35 |
Sunitinib Dose Escalation in Metastatic Renal Cell Carcinoma
|
Bruchbacher, Andreas
|
|
2019
|
|
2 |
p. 103-110
|
artikel
|
| 36 |
Surgical Complications of Presurgical Systemic Therapy for Renal Cell Carcinoma: A Systematic Review
|
McCormick, Barrett
|
|
2017
|
|
2 |
p. 115-121
|
artikel
|
| 37 |
The Current Status of Kidney Cancer Urine Markers – A Systematic Review
|
Köditz, Barbara
|
|
|
|
2 |
p. 137-142
|
artikel
|
| 38 |
The Emerging Role of Combination Angiogenesis Inhibitors and Immune Checkpoint Inhibitors in the Treatment of Metastatic Renal Cell Cancer
|
Nizam, Amanda
|
|
2019
|
|
2 |
p. 81-91
|
artikel
|
| 39 |
The Evolution of Clinical Trials in Renal Cell Carcinoma: A Status Report for 2013–2016 from the ClinicalTrials.gov Website
|
Ghatalia, Pooja
|
|
2017
|
|
2 |
p. 151-159
|
artikel
|
| 40 |
Tissue Expression of Erythropoietin Predicts Survival Rates in Clear Cell Renal Cell Carcinoma
|
Ferreira, Daniel Beltrame
|
|
2017
|
|
2 |
p. 143-149
|
artikel
|
| 41 |
Toxicity of Checkpoint Inhibition in Advanced RCC: A Systematic Review
|
Ornstein, Moshe C.
|
|
2017
|
|
2 |
p. 133-141
|
artikel
|
| 42 |
Translating Metabolic Reprogramming into New Targets for Kidney Cancer
|
Abu Aboud, Omran
|
|
2017
|
|
2 |
p. 93-97
|
artikel
|
| 43 |
Twitter as a Tool to Spread Communication Regarding Genitourinary Cancers During the COVID-19 Pandemic
|
Salgia, Sabrina
|
|
|
|
2 |
p. 73-78
|
artikel
|
| 44 |
What Comes After Immuno-Oncology Therapy for Kidney Cancer?
|
Zahoor, Haris
|
|
2019
|
|
2 |
p. 93-102
|
artikel
|
| 45 |
What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators’ Preferences in the SORCE Trial
|
Lawrence, Nicola J.
|
|
2018
|
|
2 |
p. 123-131
|
artikel
|
| 46 |
What We Have Learnt from CARMENA and SURTIME and What Should Be Done Differently in Future Trials on Cytoreductive Nephrectomy
|
Zondervan, Patricia J.
|
|
|
|
2 |
p. 95-103
|
artikel
|
Tijdschrift beschrijving